Tenosynovial Giant Cell Tumor Diagnosis and Systemic Therapy: Interprofessional Strategies for Enhanced Outcomes

What you'll learn

Course overview

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm of the synovium, bursae, and tendon sheaths that can lead to chronic pain, recurrent joint swelling, progressive functional impairment, and irreversible joint destruction. Localized TGCT can often be effectively managed with surgical excision; however, diffuse TGCT is associated with a substantial risk of recurrence after surgery. Recent advances have led to the approval of systemic therapies targeting the CSF-1/CSF1R signaling pathway for patients with symptomatic TGCT that is not amenable to surgery. These CSF1R inhibitors have demonstrated meaningful improvements in tumor response, range of motion, physical function, and patient-reported outcomes. To individualize treatment decisions in a rapidly changing therapeutic landscape, clinicians must navigate important differences in toxicity profiles and monitoring requirements to optimize long-term outcomes (Stacchiotti et al, 2023; Assi et al, 2025). In this Virtual Tumor Board activity, Brian E. Brigman, MD, PhD; Jason L. Hornick, MD, PhD; Robert A. Lefkowitz, MD; and Richard F. Riedel, MD, explore interprofessional strategies to equip the multidisciplinary team to accurately diagnose localized and diffuse TGCT, integrate evolving consensus recommendations, and individualize treatment decisions for enhanced outcomes in TGCT.